Nephrotoxicity after radionuclide therapies

Radioligand therapies have opened new treatment avenues for cancer patients. They offer precise tumor targeting with a favorable efficacy-to-toxicity profile. Specifically, the kidneys, once regarded as the critical organ for radiation toxicity, also show excellent tolerance to radiation doses as hi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ashwin Singh Parihar, Sejal Chopra, Vikas Prasad
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Renal toxicity Acute kidney injury Chronic CKD PRRT RLT Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/618d9c1b23a94e0880576740cf8333fc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:618d9c1b23a94e0880576740cf8333fc
record_format	dspace
spelling	oai:doaj.org-article:618d9c1b23a94e0880576740cf8333fc2021-11-28T04:29:56ZNephrotoxicity after radionuclide therapies1936-523310.1016/j.tranon.2021.101295https://doaj.org/article/618d9c1b23a94e0880576740cf8333fc2022-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1936523321002862https://doaj.org/toc/1936-5233Radioligand therapies have opened new treatment avenues for cancer patients. They offer precise tumor targeting with a favorable efficacy-to-toxicity profile. Specifically, the kidneys, once regarded as the critical organ for radiation toxicity, also show excellent tolerance to radiation doses as high as 50–60 Gy in selected cases. However, the number of nephrons that form the structural and functional units of the kidney is determined before birth and is fixed. Thus, loss of nephrons secondary to any injury may lead to an irreversible decline in renal function over time. Our primary understanding of radiation-induced nephropathy is derived from the effects of external beam radiation on the renal tissue. With the growing adoption of radionuclide therapies, considerable evidence has been gained with regard to the occurrence of renal toxicity and its associated risk factors. In this review, we discuss the radionuclide therapies associated with the risk of nephrotoxicity, the present understanding of the factors and mechanisms that contribute to renal injury, and the current and potential methods for preventing, identifying, and managing nephrotoxicity, specifically acute onset nephropathies.Ashwin Singh PariharSejal ChopraVikas PrasadElsevierarticleRenal toxicityAcute kidney injuryChronicCKDPRRTRLTNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENTranslational Oncology, Vol 15, Iss 1, Pp 101295- (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Renal toxicity Acute kidney injury Chronic CKD PRRT RLT Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Renal toxicity Acute kidney injury Chronic CKD PRRT RLT Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ashwin Singh Parihar Sejal Chopra Vikas Prasad Nephrotoxicity after radionuclide therapies
description	Radioligand therapies have opened new treatment avenues for cancer patients. They offer precise tumor targeting with a favorable efficacy-to-toxicity profile. Specifically, the kidneys, once regarded as the critical organ for radiation toxicity, also show excellent tolerance to radiation doses as high as 50–60 Gy in selected cases. However, the number of nephrons that form the structural and functional units of the kidney is determined before birth and is fixed. Thus, loss of nephrons secondary to any injury may lead to an irreversible decline in renal function over time. Our primary understanding of radiation-induced nephropathy is derived from the effects of external beam radiation on the renal tissue. With the growing adoption of radionuclide therapies, considerable evidence has been gained with regard to the occurrence of renal toxicity and its associated risk factors. In this review, we discuss the radionuclide therapies associated with the risk of nephrotoxicity, the present understanding of the factors and mechanisms that contribute to renal injury, and the current and potential methods for preventing, identifying, and managing nephrotoxicity, specifically acute onset nephropathies.
format	article
author	Ashwin Singh Parihar Sejal Chopra Vikas Prasad
author_facet	Ashwin Singh Parihar Sejal Chopra Vikas Prasad
author_sort	Ashwin Singh Parihar
title	Nephrotoxicity after radionuclide therapies
title_short	Nephrotoxicity after radionuclide therapies
title_full	Nephrotoxicity after radionuclide therapies
title_fullStr	Nephrotoxicity after radionuclide therapies
title_full_unstemmed	Nephrotoxicity after radionuclide therapies
title_sort	nephrotoxicity after radionuclide therapies
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/618d9c1b23a94e0880576740cf8333fc
work_keys_str_mv	AT ashwinsinghparihar nephrotoxicityafterradionuclidetherapies AT sejalchopra nephrotoxicityafterradionuclidetherapies AT vikasprasad nephrotoxicityafterradionuclidetherapies
_version_	1718408381412147200

Nephrotoxicity after radionuclide therapies

Ejemplares similares